Provided by Tiger Trade Technology Pte. Ltd.

Aptevo Therapeutics

1.87
+0.04002.19%
Volume:36.20K
Turnover:67.60K
Market Cap:3.37M
PE:-0.03
High:1.92
Open:1.83
Low:1.81
Close:1.83
52wk High:48.78
52wk Low:1.37
Shares:1.80M
Float Shares:1.65M
Volume Ratio:0.10
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-58.0829
EPS(LYR):-82.2951
ROE:-420.34%
ROA:-111.49%
PB:0.56
PE(LYR):-0.02

Loading ...

Aptevo Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Aug 01

Aptevo Therapeutics - Announces New Solid Tumor Strategy - SEC Filing

THOMSON REUTERS
·
Jul 28

Aptevo Therapeutics - Files Patent Application for Nectin-4 X Pd-L1 Dual-Targeting Backbone - SEC Filing

THOMSON REUTERS
·
Jul 28

Aptevo Files Patent for Nectin-4 X PD-L1 Dual-targeting Backbone for Solid Tumor Therapies

Reuters
·
Jul 27

Aptevo Therapeutics Secures Grant for APVO451 Development

TIPRANKS
·
Jul 01

Aptevo Therapeutics - Enters Grant Award Agreement with Andy Hill Care Fund - SEC Filing

THOMSON REUTERS
·
Jul 01

Aptevo Therapeutics - Care Fund to Provide $1.5 Mln Funding for Apvo451 Ind-enabling Studies - SEC Filing

THOMSON REUTERS
·
Jul 01

Aptevo Wins $1.5 Million Andy Hill CARE Fund Grant for Apvo451 Ind-enabling Work

Reuters
·
Jun 30

Aptevo Therapeutics Posts Investor Presentation on Multispecific Immunotherapies for Cancer, Led by Mipletamig in AML

Reuters
·
Jun 26

Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc

Reuters
·
Jun 22

Aptevo Therapeutics files Form 3 for SVP, CSO Mary Jo Janatpour

Reuters
·
May 29

Aptevo Therapeutics names Mary Janatpour senior vice president, chief scientific officer

Reuters
·
May 28

Aptevo, Niowave form 50/50 radiopharmaceutical oncology collaboration

Reuters
·
May 27

Aptevo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Aptevo net loss widens to $6.7 million in Q1 FY26; operating cash outflow rises to $8 million

Reuters
·
May 14

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

TIPRANKS
·
May 14

Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection

Reuters
·
May 13

Aptevo Therapeutics Inc expected to post a loss of $5.60 a share - Earnings Preview

Reuters
·
May 09

Aptevo says mipletamig combo shows 81% remission in frontline AML trial cohort 5

Reuters
·
May 06

Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)

TIPRANKS
·
Mar 27